Tivozanib: First Global Approval
Compliance with Ethical Standards Funding: The preparation of this review was not supported by any external funding. Conflicts of interest : During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comm...
| Main Author: | |
|---|---|
| Format: | Article in Journal/Newspaper |
| Language: | unknown |
| Published: |
Adis Journals
2018
|
| Subjects: | |
| Online Access: | https://dx.doi.org/10.6084/m9.figshare.6124907 https://adisjournals.figshare.com/articles/Tivozanib_First_Global_Approval/6124907 |
| Summary: | Compliance with Ethical Standards Funding: The preparation of this review was not supported by any external funding. Conflicts of interest : During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Esther Kim is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest. Additional information about this Adis Drug Review can be found here. Abstract Tivozanib (Fotivda®) is an oral, potent and highly selective vascular endothelial growth factor receptor (VEGFR) inhibitor that has been approved in the EU, Iceland and Norway for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mammalian target of rapamycin (mTOR) pathway inhibitor-naive following disease progression after one prior treatment with cytokine therapy for advanced RCC. Tivozanib is at various stages of development in other countries for advanced RCC and advanced solid tumours. This article summarizes the milestones in the development of tivozanib leading to this first global approval in Europe for the treatment of adults with advanced RCC. Access to the full article can be found here. © Springer International Publishing AG, part of Springer Nature 2017 |
|---|